Huawei has recently collaborated with Ruijin Hospital, affiliated with the School of Medicine, Shanghai Jiao Tong University, to officially launch the new RuiPath 2.0 AI pathology model. A grand certification ceremony was held on-site, announcing that the model has been officially deployed in more than 90 hospitals across the country for practical application.

As a new advancement in the field of medical AI, RuiPath 2.0 has achieved significant improvements in core diagnostic capabilities. Its biggest highlight is its enhanced ability to identify rare and uncommon subtypes of common cancers, effectively addressing complex challenges such as missed or misdiagnoses in traditional pathological diagnosis.

In addition, the development team is further exploring the application of the multi-modal generative foundation model in pathology, particularly in the complex clinical scenario of lymphoma, aiming to provide doctors with more accurate and efficient intelligent decision-making support tools.